(Q33327900)

25 July 2017

title

Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial (English)

1 reference

non-small-cell lung carcinoma

25 July 2017

main subject

phase I clinical trial

0 references

1 reference

inferred from title

author

Sabine Zöchbauer-Müller

object named as

S Zöchbauer-Müller

8

0 references

author name string

G Krajnik

1

1 reference

25 July 2017

W Wein

2

1 reference

25 July 2017

R Greil

3

1 reference

25 July 2017

F Marhold

4

1 reference

25 July 2017

A Mohn-Staudner

5

1 reference

25 July 2017

F Kummer

6

1 reference

25 July 2017

R Malayeri

7

1 reference

25 July 2017

H Huber

9

1 reference

25 July 2017

R Pirker

10

1 reference

25 July 2017

publication date

1 November 1998

1 reference

European Journal of Cancer

25 July 2017

published in

1 reference

25 July 2017

volume

34

1 reference

25 July 2017

issue

12

1 reference

25 July 2017

page(s)

1977-1980

1 reference

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900235-4

7 January 2021

10.1016/S0959-8049(98)00235-4

Identifiers

DOI

1 reference

25 July 2017

1 reference